Anti-aging supplements that have human evidence in 2026

Walk down a longevity aisle and biology starts to look settled. On labels and podcasts, capsules promise younger cells, calmer inflammation, sharper memory, sturdier mitochondria and a biological age that seems to run backward on command. Suresh Rattan, a biogerontologist at Aarhus University, came away with a cooler answer after surveying the anti-ageing field for his evidence review and discussing it with New Scientist. The cupboard is not empty. The shortlist is just much shorter than the shelf.

“At present using one or more nutritional and other supplements… is mostly an act of faith and hope”

Suresh Rattan, New Scientist

Rattan’s caution matters because the best human data in 2026 do not point to a glamorous longevity stack. They point to modest signals in older adults, mostly from daily multivitamins and, in a narrower setting, omega-3. The 2026 Nature Medicine COSMOS substudy by JoAnn Manson and colleagues does not show that a pill has cracked aging. Instead, 958 people inside a 21,442-person trial had slightly slower movement on two biological-age measures while taking a multivitamin.

Daniel Belsky, an aging researcher at Columbia, reads the same results with the brakes on. In a commentary on the COSMOS paper and a separate interview with C&EN, he argued that shifting an epigenetic clock is not the same as adding healthy years. The argument now is not whether biomarkers can move. They can. Harder to answer is whether those movements later mean fewer heart attacks, less frailty, delayed dementia or longer disability-free life.

“People should not read this study and think, oh, I should take a multivitamin.”

Daniel Belsky, C&EN

Vitalspell’s version of the question is stricter than the supplement market’s. Which anti-aging supplements have human evidence, and what kind of evidence is it? The answer is useful because it is less exciting than the sales copy.

The market sells lifespan, the data mostly measure proxies

A fair reading of the literature starts by separating plausible mechanisms from proven outcomes. Longevity marketing sells lifespan. Most strong trials still measure proxies: DNA methylation clocks, memory scores or intermediate disease risks. Useful as they can be, those endpoints do not settle the thing readers usually mean by aging: staying physically and cognitively intact for longer.

The mismatch is why the anti-aging shelf can look crowded while the evidence stays thin. The Springer volume on healthy longevity interventions surveys more than 250 compounds and drug candidates. Many sound plausible in animals, cell cultures or mechanistic essays. Far fewer have repeated human signals, and fewer still have shown that older adults actually do better over years rather than weeks.

For businesses, that gap has become part of the model. Recent ABC Health reporting on anti-ageing peptides and NAD-linked claims found a sales pitch running well ahead of strong outcome data. Rattan’s audit asks a plainer question: if the endpoint is human healthspan rather than enthusiasm, which names survive? Very few.

The shortlist starts with multivitamins

Multivitamins keep reappearing on the evidence ledger for an unfashionable reason. The signal has shown up more than once, in older adults, on cognitive and aging measures that sit near clinical relevance. Still, a daily multivitamin is not a longevity breakthrough. It is one of the rare familiar products with something sturdier than rodent theory.

In the 2026 Nature Medicine paper from the COSMOS subgroup, Manson and colleagues tracked 958 participants with several DNA methylation clocks. Compared with placebo, the multivitamin arm showed a yearly change of -0.113 years on PCGrimAge and -0.214 years on PCPhenoAge. Put plainly, the effect was measured in months, not years. In a category where many claims disappear as soon as people enter the study, months still count for something.

COSMOS also has a second line of evidence. In a 2024 American Journal of Clinical Nutrition report, the broader trial program found that multivitamin-mineral supplementation was associated with better global cognition, episodic memory and executive function in older adults. It also pooled three COSMOS cognitive studies in a meta-analysis. No, that does not prove a multivitamin slows aging everywhere in the body. It does make the signal harder to dismiss as one odd clock result.

A more interesting possibility is mundane. Could the benefit reflect correction of quiet nutrient shortfalls rather than some age-reversal property? Possibly. Older adults absorb, eat and metabolize differently than younger people, and the COSMOS results may fit that explanation better than any Silicon Valley story about longevity hacking. If so, the practical lesson is not “buy an anti-aging pill.” It is that the least futuristic product on the shelf may be the one with the most defensible data.

Howard Sesso, another COSMOS investigator, has been careful not to turn the trial into advice. In explaining the biological-age paper, he framed the findings as a reason to keep testing, not as a consumer verdict.

“More clinical trials are needed to understand the effects of lifestyle and pharmacologic interventions on biological aging captured through epigenetics and other biomarkers.”

Howard Sesso, Medical News Today

Omega-3 looks better in combination than in isolation

Omega-3 survives the audit too, though in a narrower and less marketable way. Better phrased: the 2024 Nature Aging analysis from DO-HEALTH found small favorable shifts in DNA methylation clocks, with some of the more interesting movement when omega-3 was paired with vitamin D and exercise.

Again, the scale was modest. Across the intervention arms, the reported epigenetic age-retardation range was about 2.9 to 3.8 months. Not nothing. Also not enough for a cautious newsroom to say omega-3 extends healthspan. The trial says biological-age metrics can move a little under a specific regimen in older adults. It does not say that a pharmacy-counter bottle buys more active years.

DO-HEALTH also cuts against the supplement industry’s favorite story, the lone hero ingredient. Its additive effect on PhenoAge appeared when omega-3 sat inside a bundle with vitamin D and exercise. A nutrient can be real without being singular. Awkward copy for marketing, but often closer to human physiology.

For evidence analysts, omega-3 is useful because it resists simplification. It belongs on the shortlist, but only with footnotes. Biomarker-heavy, population-specific and tangled up with other behaviors. Readers looking for certainty may hear that as a weakness. Readers looking for honesty should hear the difference between a clinical paper and an advertisement.

Why the rest of the aisle still falls short

So where does that leave the compounds that dominate longevity podcasts and premium stacks: NAD precursors, resveratrol blends, spermidine jars, designer peptide programs and this quarter’s new mitochondrial support formula? Mostly where they were before. Mechanism-rich, but thinner on replicated human outcomes. The problem is not that every idea is absurd. It is that anti-aging claims deserve a much higher evidence threshold than they usually get.

NAD is the current example. Consumers hear a persuasive biochemical story about declining NAD levels, cellular repair and energy metabolism. A recent ABC Health report on longevity clinics and NAD-linked claims landed on the same unease that serious researchers do: marketing has moved faster than proof. Trials may show shifts in laboratory markers or short-term physiology, but that is still a long way from knowing whether a healthy adult stays stronger, sharper or freer of age-related disease because of a supplement.

Rattan’s broader audit helps explain why so many candidates stall here. Once the endpoint changes from “does a marker budge?” to “does a person function better for longer?”, the literature gets small fast. Some interventions never reach large randomized trials. Others reach them without enough duration, participants or consistency to support a confident longevity claim. The anti-aging market is full of compounds with biographies before they have resumes.

For that reason, a skeptical evidence audit should not become a shopping guide. A short list is not a recommended stack. Multivitamins and omega-3 look more defensible than most rivals, but that says as much about the weakness of the category as the strength of the leaders. The public conversation tends to hear “best evidence” as “proven.” In longevity science, those are different sentences.

What the clock studies can and cannot tell you

The hardest part of reading anti-aging studies in 2026 is not the statistics. It is semantic drift. Biological-age clocks are getting better at compressing complex physiology into a number, and they may become useful surrogate endpoints. For now, they remain one layer removed from the everyday outcomes that make aging meaningful.

Belsky’s criticism starts there. A slower clock does not automatically mean a slower life course. Different clocks capture different kinds of risk, and normal variation can make small effects look cleaner on paper than they feel in a clinic. His skeptic’s question still lacks a strong answer: what evidence shows a change in GrimAge or DunedinPACE produces fewer real-world events? Researchers are building that bridge. They have not crossed it.

Caution does not make biomarker work pointless. It explains why the field keeps returning to it. Recent coverage of epigenetic-clock research in New Scientist shows how quickly these measures are moving from specialist tools into mainstream health talk. They are attractive because hard aging outcomes take years to accumulate. Speed is not certainty. A faster readout can help science move while still being an incomplete guide for consumers.

So which anti-aging supplements actually have human evidence in 2026? Answer: fewer than the aisle suggests. Daily multivitamins have the clearest repeated signal in older adults, spanning cognition and epigenetic aging. Omega-3 has a smaller, context-dependent case, strongest in combination strategies like DO-HEALTH. After that, the category becomes progressively more speculative.

Anyone waiting for a clean longevity pill will find that answer disappointing. It should also be reassuring. In a field that sells certainty at premium prices, useful evidence narrows the claim. Human aging is messy. The shortlist should be modest in effect, specific about endpoints and honest about what nobody knows yet. In 2026, that is what “actually has human evidence” looks like.

References

1. Manson JE, Sesso HD, et al. Effects of daily multivitamin-multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial. Nature Medicine. 2026. https://www.nature.com/articles/s41591-026-04239-3
2. Manson JE, Sesso HD, et al. Effect of multivitamin-mineral supplementation versus placebo on cognitive function: results from the clinic subcohort of the COcoa Supplement and Multivitamin Outcomes Study randomized clinical trial and meta-analysis of three cognitive studies within COSMOS. The American Journal of Clinical Nutrition. 2024. https://www.sciencedirect.com/science/article/abs/pii/S0002916523663427?via%3Dihub
3. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging. 2024. https://www.nature.com/articles/s43587-024-00793-y